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Lars Viktrup*†, Risa P Hayes†, Ping Wang† and Wei ShenAbstract
Background: Lower urinary tract symptoms (LUTS) in aging men are often associated with benign prostatic
hyperplasia (BPH). While regulatory evaluations of treatment benefit require an assessment of specific symptoms,
a simpler approach to measuring patients’ perceptions of severity and symptom change may be particularly useful
for clinical practice. The aim of this study was to provide evidence of the validity of the 1-item Patient Global
Impression of Severity (PGI-S) and Improvement (PGI-I) questionnaires for use as outcome measures in the
treatment of BPH-LUTS.
Methods: This was a secondary analysis of data from 4 randomized placebo-controlled 12-week trials evaluating
tadalafil for the treatment of BPH-LUTS (N=1694). Visit 2 (V2 [beginning of a 4-week placebo lead-in period]) and
endpoint assessments included International Prostate Symptom Score (IPSS), IPSS Quality of Life Index (IPSS-QoL),
BPH Impact Index (BII), and peak urine flow (Qmax). PGI-S was only administered at V2 and PGI-I only at endpoint.
Associations between the PGI-S or the PGI-I and the other assessments were analyzed by calculating Spearman rank
correlation coefficients and performing analysis of variance (ANOVA).
Results: Spearman correlation coefficients were 0.43, 0.43, 0.53, and −0.09, between the PGI-S and IPSS, IPSS-QoL,
BII, and Qmax baseline results (all P<0.001). Similar results were seen across race, ethnicity, and baseline severity
(moderate LUTS versus severe LUTS). IPSS, IPSS-QoL, BII baseline scores (P <0.001) and Qmax values (P=0.003) were
significantly different among the 4 PGI-S severity levels. Spearman correlation coefficients were 0.56, 0.53, 0.47 and
−0.15 between the PGI-I and change in IPSS, IPSS-QoL, BII scores, and Qmax values from baseline to endpoint (all
P<0.001). Similar results were seen across race, ethnicity, and baseline severity. Change in IPSS, IPSS-QoL, BII scores,
and Qmax values (P<0.001) were significantly different among the PGI-I levels (i.e., patient perception of change in
urinary symptoms).
Conclusions: This study demonstrated patients’ overall perceptions of their severity and change in BPH-LUTS can
be captured in a way that is simple, valid, and easily administered in a research setting or clinical practice. Clinical
parameters are weakly associated with patients’ perception of urinary symptoms, emphasizing the importance of a
patient-reported assessment in the evaluation of BPH-LUTS treatment benefit.
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Lower urinary tract symptoms (LUTS), often associated
with benign prostatic hyperplasia (BPH), are common in
aging men worldwide with a severity that seems to be
similar across countries [1]. Symptoms may belong to 1
of 3 domains: voiding (obstructive) symptoms which in-
clude slow stream, splitting/spraying of stream, intermit-
tency, hesitancy, straining, and terminal dribble; storage
(irritative) symptoms which include frequency, nocturia,
urgency, and incontinence; and postmicturition symp-
toms which include feeling of incomplete emptying and
postmicturition dribble [2]).
Several validated questionnaires have been developed
in collaboration with The American Urology Association
(AUA) to assess the severity and treatment effect in men
with BPH-LUTS. One such instrument is the International
Prostate Symptom Score (IPSS) which is commonly used
to assess therapeutic efficacy of BPH therapy [3,4] and has
been translated into multiple languages. The IPSS QoL
Index is an additional question usually included at the end
of the IPSS questionnaire, though not part of the total
IPSS score [5]. The AUA committee also developed the
BPH Impact Index (BII) to assess the impact of LUTS sug-
gestive of BPH on patient health and functioning [4]. The
BII has recently been further validated based on several
tadalafil clinical studies [6,7]. While the IPSS question-
naire is accepted as a critical component in BPH-LUTS
research, the IPSS-QoL and BII (assessments of symptom
burden and impact) are less frequently used.
In light of the need for a simple and easy-to-use vali-
dated questionnaire to assess patients’ overall perception
of their condition, the Patient’s Global Impressions of Se-
verity (PGI-S) and Patient’s Global Impressions of Improve-
ment (PGI-I) questionnaires were included in several
tadalafil BPH-LUTS clinical studies conducted worldwide.
The PGI-S and PGI-I respectively are 1-item questionnaires
that ask an individual patient to rate the severity of a spe-
cific condition (single-state scales) at baseline and or to
rate at endpoint the perceived change in his/her condition
in response to therapy (transition scales) [8,9]. These types
of measures have been implemented and/or validated in
clinical studies of patients with stress incontinence [9],
urogenital prolapse [10] and other non-urological diseases
[11]. The aim of this study was to provide evidence that
supports the validity of these two 1-item questionnaires
for LUTS suggestive of BPH by correlating them with other
subjective and objective measures of symptom severity or
changes in severity in tadalafil placebo-controlled studies.
Methods
Study design and participants
This was a secondary analysis of data from 4 clinical
trials. Details of the study designs and populations have
previously been published [12-15].Study 1 (LVHJ) was a randomized, double-blind, pla-
cebo-controlled, parallel-design multinational study to
evaluate the efficacy and safety of daily tadalafil 5 mg
once daily for 12 weeks. Study participants were men
with LUTS secondary to BPH (BPH-LUTS) residing in
Argentina, Germany, Italy, Mexico, or the United States
(Clinicaltrials.gov: NCT00827242 [12]).
Study 2 (LVHR) was a randomized, double-blind, 3-
group, placebo-controlled, parallel-design, multinational
study to evaluate the efficacy and safety of tadalafil 2.5-
and 5-mg once-daily dosing for 12 weeks for the treat-
ment of erectile dysfunction (ED) and BPH-LUTS. Study
participants were men with both ED and BPH-LUTS re-
siding in Canada, France, Germany, Greece, Italy, Mexico,
Portugal, Russia, and the United States (Clinicaltrials.gov:
NCT00855582 [13]).
Study 3 (LVHB) was a randomized, double-blind, 4-
group, placebo and tamsulosin 0.2 mg controlled, paral-
lel design, multinational study to evaluate the efficacy
and safety of tadalafil 2.5 mg and 5 mg once-a-day dosing
for 12 weeks in men with BPH-LUTS residing in Japan,
Korea, and Taiwan (Clinicaltrials.gov: NCT00861757 [14]).
Study 4 (LVHT) was a randomized, double-blind, 3-
group, placebo-controlled, parallel-design, pilot study to
evaluate the efficacy and safety of tadalafil 5 mg and
tamsulosin 0.2 mg once-a-day dosing for 12 weeks in
men with BPH-LUTS residing in Korea (Clinicaltrials.
gov: NCT00540124 [15]).
Men who were at least 45 years of age, with moderate to
severe LUTS due to BPH and evidence of bladder obstruc-
tion, were eligible to participate in all 4 studies. ED was an
entry criterion only in Study 2 (LVHR). The 4 studies were
in compliance with the Helsinki Declaration.
In each study, participants were screened at V1. In all
4 studies, there was a 2- (Study 3, LVHB) or 4-week
screening/washout period (V1-V2), a 4-week placebo
lead-in period (V2-V3), and a 12-week double-blinded
treatment period (V3 to last visit). At V2, participants in
all studies were required to have an IPSS ≥13 and a uro-
flowmetry measure of urinary peak flow rate (Qmax) ≥4
to ≤15 ml/second on a voided volume of 125 mL to con-
tinue in the study. One study (Study 3, LVHB) also re-
quired a minimum total prostate volume of 20 mL. V3
(randomization) initiated the double-blind active-treat-
ment placebo-controlled 12-week period. Patient charac-
teristics were assessed at V2.Clinical measures
Postvoid residual volume (PVR) and prostate-specific
antigen (PSA) were assessed in all studies, but not con-
sistently carried out at the V2. The change in peak urine
flow rate (Qmax) from randomization (V3) to endpoint
was a secondary objective in all the studies. Changes in
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ment at V2 and at endpoint.
Patient-reported measures
The change in IPSS from randomization (V3) to endpoint
was the primary objective in all the studies; changes in
IPSS-QoL, BII and Qmax from V3 to endpoint were
secondary objectives. Changes in these patient-reported
outcomes included in this validation were based on as-
sessment at V2 and at endpoint.
The PGI-I also was a secondary objective, with 1 assess-
ment at endpoint. PGI-S assessed participants’ perception
of symptom severity at V2 and was an exploratory par-
ameter. The Korean pilot study (Study 4) did not assess
BII at V2 and the BII scores could therefore not be used
from this study to correlate with PGI-S.
The IPSS is a self-administered 7-item urinary symp-
tom severity scale about symptoms occurring over the
past month (Additional file 1; International Prostate
Symptom Score). The urinary symptoms can be categor-
ized into voiding, storage and post-micturition symp-
toms. Item scores are summed for a total IPSS score
that ranges from 0 to 35 with a higher score indicating
more severe symptoms.
The IPSS-QoL is a single question: “If you were to
spend the rest of your life with your urinary condition
just the way it is now, how would you feel about that?”
with responses scored as follows: “delighted” (0), “pleased”
(1), “mostly satisfied” (2), “mixed about equally satisfied
and dissatisfied” (3), “mostly dissatisfied” (4), “unhappy”
(5), and “terrible” (6) (Additional file 1; International
Prostate Symptom Score).
The BII is a self-administered validated questionnaire
with 4 questions about urinary problems during the past
month regarding physical discomfort, worry about
health, how bothersome symptoms are, and whether the
symptoms are interfering with doing usual activities
(Additional file 2; BPH Impact Index). The first 3 ques-
tions are scored from 0 to 3, while the fourth is scored
from 0 to 4. Item scores are summed for a BII total
score that ranges from 0 to 13, with higher scores indi-
cating more bother or problems associated with urinary
symptoms within the previous month.
PGI-I is a 1-item questionnaire designed to assess the
patient’s impression of changes in urinary symptoms.
The PGI-I asks the patient to best describe how his urin-
ary symptoms are now, compared with how they were
before he began taking medication in the study. (“Check
the one number that best describes how your urinary
symptoms are now, compared with how they were be-
fore you began taking medication in this study”). The
patient enters his answer on a 7-point scale scored as: (1)
“very much better,” (2) “much better,” (3) “a little better,”
(4) “no change,” (5) “a little worse,” (6) “much worse,” or(7) “very much worse.” Examples of urinary symptoms
were provided based on the symptoms in the IPSS ques-
tionnaire [3] with the addition of terminal dribble and ac-
cidental urinary leakage [16]: “Urinary symptoms include
difficulties in postponing urination, having to push or
strain to begin urination, a weak urinary stream, stopping
and restarting urination several times when attempting
to urinate, prolonged urination with the end of urine
flow slowing to a trickle (terminal dribble), the feeling
that you haven’t emptied your bladder after you have fin-
ished urinating, having to urinate again less than 2 hours
after the last time you finished urinating, accidental uri-
nary leakage, or having to get up at night to urinate”. The
PGI-I was administered once at the end-of-study visit
(Week 12 or the last visit).
PGI-S is a 1-item questionnaire designed to assess
patient’s impression of disease severity. The PGI-S item
asks the respondent to best describe how his urinary
symptoms are now (“Check the one number that best
describes how your urinary symptoms are now”) on a
4-point scale scored as: “normal” (1), “mild” (2), “moder-
ate” (3), or “severe” (4) . Examples of urinary symptoms
similar to the PGI-I were provided. The PGI-S was ad-
ministered once at the beginning of the placebo lead-in
period (V2).
All patient-reported measures were originally de-
veloped in English for the United States. Therefore, lin-
guistic validations that included forward and backward
translations, review/reconciliation, and cognitive debrief-
ing with targeted patients were conducted for primary
languages spoken in the countries participating in the 4
trials. In addition, for most linguistic validations, har-
monization, a meeting in which all translations and the
original are compared to ensure cross-cultural equiva-
lence of concepts and the use of colloquial language,
was performed.
Statistical analysis
The study results for tadalafil efficacy versus placebo are
reported elsewhere [12-15].
In the current paper, because the aim of the analysis
was not to make conclusions about tadalafil efficacy, but
rather to establish construct validity of the PGI-S and
the PGI-I, tadalafil and placebo data from the 4 clinical
studies were pooled (N=1694) and analyzed. Further-
more, an evaluation of tadalafil efficacy versus placebo
would be based on changes from randomization (V3) to
endpoint, while the validation of the PGI-I per its ques-
tion ( see above) was based on changes from treatment
onset at V2 (initiating with single-blind placebo therapy)
to endpoint.
For a single-item global assessment to adequately (i.e.,
validly) assess a patient’s overall appraisal of their condi-
tion of change in their condition, its single score would
Table 1 Baseline Characteristics and Demographics
Baseline Characteristics Statistics
Total number of randomized patients, N 1694
Age, mean (SD) 63.1 (8.2)
Peak urine flow rate (Qmax)
Mild (Qmax > 15 ml/s), n (%) 11 (0.7%)
Moderate (Qmax 10–15 ml/s), n (%) 837 (50.7%)
Severe (Qmax < 10 ml/s), n (%) 802 (48.6%)
PSA (mg/L), mean (SD) 1.8 (1.6)
PVR (mL), mean (SD) 38.1 (42.0)
LUTS Severity
Moderate (IPSS 8–19), n (%) 1090 (64.4%)
Severe (IPSS >= 20), n (%) 603 (35.6%)
Race/Ethinity
Asian, n (%) 763(45.0%)
Caucasian, n (%) 861(50.8%)
Hispanic Caucasian, n (%) 164 (9.7%)
Non-Hispanic Caucasian, n (%) 697 (41.1%)
Other Race, n (%) 70 (4.1%)
SD: standard deviation; n: number of patients; PSA: Prostate-specific antigen;
PVR: post-void residual urine volume; LUTS: Lower Urinary Tract Symptoms;
Asian: from the 2 studies conducted in Asia; Caucasian/Other race: from the
2 studies conducted outside Asia. Values are from V1-V2, before enrolled into
the single-blind placebo run in period.
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also impact of that symptom burden on the patient’s life.
Therefore, we hypothesized that the PGI-S and PGI-I
scores would be significantly and meaningfully asso-
ciated with the IPSS, IPSS-QoL, and BII scores. In ad-
dition, we explored the relationship with Qmax, the only
clinical measure consistently assessed at V2 in the 4
clinical studies.
The associations between PGI-S response at V2 and
other patient-reported and clinical measures at V2 (IPSS,
IPSS-QoL, BII, and Qmax) were evaluated using 2 types
of analyses. First, Spearman rank correlation coefficients
were calculated between PGI-S and the other measures.
Spearman correlation coefficient is a nonparametric ana-
lysis which assesses how well the relationship between 2
variables can be described using a monotonic function
[17]; for example, whether patients’ perception of greater
severity, as measured by the PGI-S, is associated with
greater symptom burden as measured by IPSS. Correla-
tion coefficients range from −1.0 to 1.0. Using a criterion
suggested by Guilford and Fruchter [18], a significant
correlation coefficient ≤−0.30 or ≥0.30 between the PGI-
S and the V2 assessment of other patient-reported or
clinical measures (i.e., supportive of the validity of the
PGI-S).
The second type of analysis, unadjusted one-way ana-
lysis of variance (ANOVA), was performed to evaluate
the differences of these measures among the 4 PGI-S
categories and pair-wise comparisons were made. Identi-
cal ANOVA analyses, adjusted for covariates (e.g., age,
prior alpha blocker use, country, baseline LUTs severity)
were performed to confirm results. For all analyses, the
a priori hypotheses were that patients perceiving more
severe disease measured by PGI-S would have higher
(worse) IPSS, IPSS-QoL, and BII scores and lower
(worse) peak urine flow rate at V2.
The associations between PGI-I response at last visit
and change in IPSS, IPSS-QoL, BII, and Qmax values
from V2 to the last visit were evaluated using the same 2
types of analysis as performed with the PGI-S. For all
analyses, the a priori hypotheses were that patients who
reported change in their urinary symptoms would have
better or worse IPSS, IPSS-QoL, and BII scores or Qmax
values consistent with the direction of their perceived
change in symptoms as measured by the PGI-I.
To further provide support for the validity of the PGI-S
and PGI-I, the correlation analyses were repeated across
6 racial, ethnic, and severity subgroups: Asians versus
Caucasians, Hispanic Caucasians versus non-Hispanic
Caucasians, and LUTS severity at V2 (per IPSS classifica-
tion of moderate versus severe). Assessment of race and
ethnic subgroups was restricted within the relevant
regions: Asians were only from Asian studies; Cauca-
sians, including both Hispanic and non-HispanicCaucasians, were only from non-Asian studies). It should
be noted that these analyses were conducted to support
the validity of the PGI-S and PGI-I and not to explore
whether ethnic/racial groups differ in perception of se-
verity or response to treatment. For all analyses, partici-




A total of 1694 men were enrolled and subsequently
randomized in the 4 studies; mean age was 63.1 years
(SD = 8.2, range from 45 to 87). A total of 35.6% had se-
vere symptoms of BPH-LUTS per IPSS and 48.6% had
severe outlet obstruction per urinary peak flow rate
(Qmax) (Table 1). Participant characteristics obtained at
V2 were generally similar across studies; although in
Study 2 (LVHR), more patients had severe outlet ob-
struction per Qmax, whereas in Study 4 (LVHT), more
patients and their clinicians reported severe symptoms
(data not shown).
A total of 1692 men completed the PGI-S at V2 (be-
fore the placebo run-in period) and 1628 men completed
the PGI-I at last visit. Participants’ self-reported ratings
of urinary symptom severity using the PGI-S were 1.1%
normal, 22.2% mildly abnormal, 61.4% moderately ab-
normal, and 15.3% severely abnormal. The mean symp-
tom scores for all participants for IPSS, IPSS-QoL, BII
Table 2 Correlation between PGI-S and other baseline BPH Measures in all patients
PGI-S (baseline visit) n (%) Mean IPSS (SD) Mean IPSS-QoL (SD) Mean BII (SD) Mean Qmax (SD)
Normal 18 (1.1%) 14.9 (2.9) 2.4 (0.6) 1.1 (1.4) 10.4 (2.4)
Mild 376 (22.2%) 16.8 (3.9) 3.5 (1.1) 4.0 (2.4) 10.4 (2.7)
Moderate 1039 (61.4%) 19.8 (4.7) 4.1 (1.0) 6.7 (2.5) 9.9 (2.8)
Severe 259 (15.3%) 24.2 (5.5) 5.0 (0.9) 9.1 (2.6) 9.6 (2.9)
Overall comparison p-value <0.001 <0.001 <0.001 0.003
Pairwise comparison p-value
Normal vs. Mild 0.092 <0.001 <0.001 0.993
Normal vs. Moderate <0.001 <0.001 <0.001 0.461
Normal vs. Severe <0.001 <0.001 <0.001 0.273
Mild vs. Moderate <0.001 <0.001 <0.001 0.002
Mild vs. Severe <0.001 <0.001 <0.001 <0.001
Moderate vs. Severe <0.001 <0.001 <0.001 0.171
Spearman’s Correlation 0.43** 0.43** 0.53** −0.09**
PGI-S: Patient Global Impression of Severity; IPSS: International Prostate Symptom Scores; IPSS QoL: IPSS-Quality of Life (QoL), BII - Benign Prostatic Hyperplasia
Impact Index; Qmax: peak urine flow rate; n: number of patients; SD: Standard Deviation. Overall and pairwise comparison p-values are from analysis of variance
without adjusting for covariates. **: p<0.001.
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were 19.8, 4.1 and 6.3, respectively. The mean V2 Qmax
value was 10.0 ml/s.
Construct validity of the PGI-S
Spearman correlation coefficients calculated between
PGI-S and all variables were statistically significant
(P<0.001) and in the direction hypothesized (Table 2).
However, the correlation coefficient calculated between
PGI-S and Qmax did not reach the criterion of ≤−0.30
designated a priori as supportive of validity (Table 2).
Similar trends of correlations were observed across eth-
nicity, race and baseline severity (Table 3).
Overall comparisons among PGI-S severity responses
showed significant differences across all variables regard-
less of whether the ANOVA model was unadjusted or
adjusted for covariates. The mean IPSS score for the par-
ticipants who responded “moderate” (19.8) or “severe”
(24.2) on the PGI-S were significantly different (P<0.001)Table 3 Correlation between PGI-S and other baseline
BPH Measures across race, ethnicity and baseline severity
Spearman’s Correlation n IPSS IPSS-QoL BII Qmax
Asian 763 0.45** 0.45** 0.58** −0.06
Caucasian 860 0.42** 0.43** 0.50** −0.12**
Hispanic Caucasian 164 0.55** 0.54** 0.55** −0.14
Non-Hispanic Caucasian 696 0.38** 0.38** 0.49** −0.12*
Moderate LUTS 1088 0.35** 0.37** 0.49** −0.04
Severe LUTS 603 0.36** 0.39** 0.50** −0.11*
Asian: from the 2 studies conducted in Asia; Caucasian: from the 2 studies
conducted outside Asia.
PGI-S: Patient Global Impression of Severity; IPSS: International Prostate
Symptom Scores; IPSS QoL: IPSS-Quality of Life (QoL), BII - Benign Prostatic
Hyperplasia Impact Index; Qmax: peak urine flow rate; LUTS: Lower Urinary
Tract Symptoms; n: number of patients. **: p<0.001; *: p<0.05.from the mean scores for all other responses with
greater perceived severity corresponding to higher self-
reported symptom burden. However, the mean IPSS
scores for participants who responded “normal” (14.9) or
“mild” (16.8) were significantly different from the mean
scores for “moderate” and “severe” but not from each
other. Mean IPSS-QoL and BII scores for the PGI-S cat-
egories were all significantly different from one another
(P<0.001) with greater perceived severity corresponding
to perception of worse quality of life and greater disease
impact. Qmax values were not significantly different be-
tween participants who responded “normal” and those
who responded “mild”, or “moderate”, or “severe” on the
PGI-S, nor were they significantly different between the
participants who responded “moderate” and those who
responded “severe”. Only the Qmax values for those par-
ticipants who responded “mild” were significantly differ-
ent from the values for those who responded “moderate”
or “severe”.
Construct validity of the PGI-I
Spearman correlation coefficients calculated between
PGI-I and all variables were statistically significant
(P<0.001) and in the direction hypothesized (Table 4).
However, as with the PGI-S, the correlation coefficient
calculated between PGI-I and Qmax change did not
reach the criterion of ≤−0.30 designated a priori as sup-
portive of validity (Table 4). Similar trends of correla-
tions were observed across ethnicity, race and V2
severity (Table 5).
Overall comparisons among PGI-I responses showed
significant differences for all variables regardless of wheth-
er the ANOVA model was unadjusted or adjusted for
the covariates. However, to conduct pairwise comparisons,
Table 4 Correlation between PGI-I and other BPH Measures (change from baseline) in all patients








Very Much Better 99 (6.1%) −14.4 (5.9) −2.6 (1.6) −5.2 (3.1) 3.7 (4.9)
Much Better 443
(27.2%)
−10.9 (5.6) −2.0 (1.3) −4.0 (2.9) 4.0 (5.6)
A Little Better 632
(38.8%)
−7.0 (5.4) −1.0 (1.2) −2.3 (2.7) 3.0 (5.0)
No Change 357
(21.9%)
−3.3 (5.2) −0.3 (1.1) −0.9 (2.7) 2.1 (4.3)
A Little Worse 65 (4.0%) −0.2 (5.7) 0.0 (1.2) −0.1 (3.0) 2.0 (4.8)
Much Worse 26 (1.6%) 3.5 (5.4) 0.5 (1.1) 1.8 (2.6) 1.3 (3.1)
Very Much Worse 6 (0.4%) 6.8 (5.1) 1.0 (0.9) 4.5 (2.1) 0.1 (2.0)
Overall comparison p-value <0.001 <0.001 <0.001 <0.001
Pairwise comparison p-
value
Better vs. No change <0.001 <0.001 <0.001 <0.001
Better vs. Worse <0.001 <0.001 <0.001 0.002
No change vs. Worse <0.001 <0.001 <0.001 0.534
Spearman’s Correlation 0.56** 0.53** 0.47** −0.15**
PGI-I: Patient Global Impression of Improvement; IPSS: International Prostate Symptom Scores; IPSS QoL: IPSS-Quality of Life (QoL), BII - Benign Prostatic
Hyperplasia Impact Index; Qmax: peak urine flow rate; n: number of patients; SD: Standard Deviation. Overall and pairwise comparison p-values are from analysis
of variance without adjusting for covariates. **: p<0.001.
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worse” N=6) necessitated the collapsing of the 3 PGI-I
response categories representing improvement (“a little
better,” “much better,” and “very much better”) and the
corresponding response categories representing worsen-
ing into 1 category each, “Better” and “Worse,” respect-
ively. Mean IPSS, IPSS-QoL and BII change scores were
significantly different (P<0.001) among all 3 response cat-
egories with improvement in symptoms, perceived QoL,
and BPH impact corresponding to PGI-I “Better” re-
sponses, and worsening in symptoms, perceived QoL,
and BPH impact corresponding to PGI-I “Worse” re-
sponses. Mean change in Qmax values for participants
who responded on the PGI-I as improved or“Better” wereTable 5 Correlation between PGI-I and other BPH
Measures (change from baseline) across race, ethnicity
and baseline severity
Spearman’s Correlation n IPSS IPSS-QoL BII Qmax
Asian 747 0.55** 0.52** 0.43** −0.15**
Caucasian 816 0.57** 0.54** 0.49** −0.13**
Hispanic Caucasian 158 0.65** 0.45** 0.49** −0.15
Non-Hispanic Caucasian 658 0.55** 0.54** 0.49** −0.14*
Moderate LUTS 1050 0.53** 0.52** 0.44** −0.12**
Severe LUTS 577 0.62** 0.54** 0.51** −0.19**
Asian: from the 2 studies conducted in Asia; Caucasian: from the 2 studies
conducted outside Asia.
PGI-I: Patient Global Impression of Improvement; IPSS: International Prostate
Symptom Scores; IPSS QoL: IPSS-Quality of Life (QoL), BII - Benign Prostatic
Hyperplasia Impact Index; Qmax: peak urine flow rate; LUTS: Lower Urinary
Tract Symptoms; n: number of patients. **: p<0.001; *: p<0.05.significantly higher than those for participants who re-
sponded as “No Change” or classified as responding
“Worse”. However, there were no significant differences
between those who responded “No Change” and those
who responded “Worse”.
Discussion
In men participating in clinical trials evaluating treat-
ment for LUTS, evidence for the validity of the PGI-S
and PGI-I was provided through the associations ob-
served with other symptom and quality of life assess-
ments, but not with peak flow rate severity or changes.
The validation of these 2 questionnaires supports their
utility as simple tools in research or for clinicians who
treat patients with BPH- LUTS.
Symptom severity at V2 as assessed by PGI-S and
changes in symptoms as assessed by PGI-I at endpoint
were moderately to highly correlated with scores from
other BPH patient-reported measures. Further support
for the validity of the PGI-S and PGI-I was provided
when similar associations were observed across ethnicity
and V2 severity (as categorized by IPSS scores). (Tables 3
and 5).
The association with the clinical parameter, peakflow
(Qmax), was weak both at V2 and endpoint (Tables 2
and 4). The weak correlation between subjective scores
such as PGI-S and PGI-I and Qmax or Qmax change is
not surprising. When Qmax was evaluated in the re-
cently updated AUA BPH treatment guidelines 2010, the
AUA panel concluded that Qmax correlates poorly with
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weak, patient-oriented outcome in that the patient only
marginally experiences flow rate differences. The AUA
panel also found that Qmax is not particularly useful
from a diagnostic point of view [4]. A high correlation
between symptoms scores but a weak correlation with
objective parameters (including Qmax) has been re-
ported before in studies within the same BPH disease
area as well as in other areas such as female stress in-
continence. When Angalakuditi and coauthors validated
the BII instrument against IPSS, IPSS-QoL, PVR and
Qmax in 12-week placebo-controlled studies, they found
a high correlation with patient-reported symptoms and a
poor correlation with objective parameters [6]. Yalcin
and Bump examined the construct validity of PGI-S and
PGI-I against stress incontinence episodes (assessed with
weekly diaries), the Incontinence Quality of Life Ques-
tionnaire (I-QoL) measures, and leakage during physical
exertion (per pad test), and identified weak correlation
with the objective pad test in contrast to the higher cor-
relation with the other instruments [9]. It is interesting
to note that across different lower urinary tract condi-
tions, objective parameters do not seem to sufficiently
capture patient-reported symptoms. These findings con-
firm the need to include a patient-reported assessment
in the evaluation of urological treatment benefit.
As in this study, moderate to high correlations (0.4 to
0.6) have been shown between patient global assess-
ments and symptom measures in other therapeutic
areas. It may be expected that a global assessment of
symptom severity or change in symptom burden would
correlate more highly (e.g., >0.70) with a symptom meas-
ure; for example, the association between PGI-S and
PGI-I and the IPSS would be stronger than reported if it
adequately captured symptom burden. However, there
are factors that potentially affect the strength of the as-
sociation. One factor is the recall period for the mea-
sures. The IPSS has a month recall period in which
respondents are to recall and purportedly average their
symptom severity over that month, whereas the PGI-S
asks respondents to report current severity. At endpoint,
the IPSS asks the respondent to recall only the past
month and this is statistically compared to the respon-
dent’s recall of the month prior to V2 (in which they may
have been receiving treatment for BPH-LUTS, erectile
dysfuncion, overactive bladder, etc.), while the PGI-I asks
the respondent to remember how their symptoms were
before they believed they were receiving treatment medi-
cation and compare that to how their symptoms are cur-
rently. Without asking the participants what timeframe
they were considering when completing these instru-
ments, it is difficult to estimate the effect that the differ-
ence in recall periods has upon the strength of the
associations between the IPSS and the global assessments.Another factor that may affect the magnitude of the
correlation is that the urinary symptoms that the partici-
pants are asked to consider are not completely identical
for each questionnaire. The IPSS does not include all
urinary symptoms that could be affecting a patient with
BPH-LUTS. While in the global impression scales im-
plemented in the tadalafil clinical studies and validated
here, examples of urinary symptoms were provided based
on the symptoms in the IPSS questionnaire [3], in ad-
dition to a few other symptoms. In PGI-I and PGI-S, ter-
minal dribble was included as an example of urinary
symptoms because it has been identified as a prevalent
LUTS in many men [16] and may be associated with
BPH. Postmicturition dribble defined as urine leakage al-
most immediately after finishing urinating and walking
away from the toilet was omitted as an example of urin-
ary symptom in the PGI-S and PGI-I, since accidental
urinary leakage was already included. Dysuria was also
omitted as an example of urinary symptoms since the ex-
clusion criteria in the tadalafil studies typically would
eliminate patients with such presentation. Overall, the
different urinary symptoms provided as examples in the
PGI-S and PGI-I were not meant to be exhaustive of all
urinary symptoms or restrictive to BPH, but aimed at
providing the patient with examples of common urinary
symptoms he could experience. In contrast, the global
impression scale tested by Yalcin and Bump did not pro-
vide any examples or explanation of the urinary condi-
tion tested [9].
Despite the inherent differences between the global
assessments and the IPSS, as well as the other patient-
reported measures, the relationships observed in this
study were in the direction hypothesized and showed
the greatest changes in self-reported symptoms, quality
of life, and BPH impact for those who perceived them-
selves as improved (i.e., getting better).
A slightly different patient global assessment of improve-
ment has been included before in a placebo-controlled 1-year
study assessing changes to mono-therapy or combination-
therapy with an alpha-blocker and/or 5 alpha-reductase-
inhibitor in men with BPH-LUTS [19]. The authors
concluded that the global assessments of improvement
attested to the clinical significance of the difference in
other outcome measures [19]. While the construct valid-
ity demonstrated in the analysis presented in our paper is
applicable to a population of men with BPH-LUTS, the
validity of the PGI-S and PGI-I for men with other lower
urinary tract symptoms has not been established.
Since the development of the IPSS or BII in the begin-
ning of the nineties, the urological environment and treat-
ment culture has changed from surgery as the cornerstone
of BPH treatment to predominantly drug therapy. A
simple 1-item global questionnaire may, therefore, seem
more applicable today.
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Evidence of the construct validity of the PGI-S and PGI-I
for men with BPH-LUTS provided in this study indicates
that the 2 instruments could be a valuable and useful tool
for clinical studies and practice. While the regulatory
evaluation of treatment benefit in clinical trials may re-
quire multi-item instruments to fully describe the impact
of treatment on various symptoms [20], the PGI-S and
PGI-I can provide an overall appraisal of a patients’ con-
dition and is more practical for clinical use by its simpli-
city in administration and interpretability.
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